Core Insights - Revolution Medicines, Inc. (RVMD) is highlighted as a promising investment opportunity, particularly due to its innovative RAS(ON) platform aimed at treating difficult cancers [2][5]. Company Overview - Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing targeted therapies for cancers driven by RAS/MAPK pathway mutations using precision small-molecule inhibitors [5]. Recent Developments - Jefferies initiated coverage of RVMD with a Buy rating and set a price target of $140, significantly increased from $88, emphasizing the potential of its RAS(ON) platform [2]. - The Phase 3 RASolute 302 trial is anticipated to meet its first interim endpoints, suggesting a positive clinical and commercial outlook for the company [2]. - RVMD plans to present important updates on its pipeline of RAS(ON) inhibitors at the 2026 American Association for Cancer Research (AACR) Annual Meeting scheduled for April 17–22 in San Diego [3]. Clinical Trials and Research - New Phase 1 data for zoldonrasib in KRAS G12D mutant non-small cell lung cancer and Phase 1/2 results for daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma will be presented, showcasing the company's extensive clinical efforts [4]. - Preclinical research on next-generation catalytic RAS(ON) inhibitors will also be discussed, highlighting the company's commitment to targeting RAS-driven malignancies and overcoming treatment resistance [4].